The clinical feature and optimal treatment strategy of bone metastasis in EGFR mutated NSCLC patients

Conclusion: BoM was identified as an inferior prognostic factor for NSCLC patients with EGFR mutation, which may be due to extra thoracic metastasis. However, adding an anti-angiogenesis drug and denosumab to patients with BoM and sequential osimertinib treatment can provide survival benefits.

Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Cheng, W.-C., Chen, W.-C., Chen, C.-L., Liao, W.-C., Tu, C.-Y., Hsia, T.-C., Chen, H.-J., Chen, C.-H. Tags: Lung cancer Source Type: research